Video

Dr. Iyengar on Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Neil M. Iyengar, MD, medical oncologist, Breast Cancer, Memorial Sloan Kettering Cancer Center, discusses the use of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-low breast cancer.

HER2-low breast cancer is a newer phenotype within this disease space and other cancers, Iyengar says. Trastuzumab deruxtecan has generated activity in early-phase studies involving patients with HER2-low expressing cancers, Iyengar says. Notably, patients with triple-negative breast cancer or estrogen receptor- (ER) positive, HER2-negative breast cancer that has progressed or become endocrine insensitive are typically treated with chemotherapy, Iyengar explains.

Trastuzumab deruxtecan could represent a new therapeutic approach for patients categorized into a subgroup of low expression of HER2, Iyengar says. Future data could lead to the registration of drugs like trastuzumab deruxtecan in this space, Iyengar concludes.

Related Videos
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center